DK0988051T3 - Lyme-kombinationspræparater og anvendelser - Google Patents
Lyme-kombinationspræparater og anvendelserInfo
- Publication number
- DK0988051T3 DK0988051T3 DK98908885T DK98908885T DK0988051T3 DK 0988051 T3 DK0988051 T3 DK 0988051T3 DK 98908885 T DK98908885 T DK 98908885T DK 98908885 T DK98908885 T DK 98908885T DK 0988051 T3 DK0988051 T3 DK 0988051T3
- Authority
- DK
- Denmark
- Prior art keywords
- antigen
- pathogen
- borrelia burgdorferi
- compositions
- applications
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 241000589969 Borreliella burgdorferi Species 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 244000052769 pathogen Species 0.000 abstract 3
- 230000001717 pathogenic effect Effects 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 241000282465 Canis Species 0.000 abstract 1
- 241000282472 Canis lupus familiaris Species 0.000 abstract 1
- 241000711573 Coronaviridae Species 0.000 abstract 1
- 208000000655 Distemper Diseases 0.000 abstract 1
- 241000283086 Equidae Species 0.000 abstract 1
- 241000283073 Equus caballus Species 0.000 abstract 1
- 241000282324 Felis Species 0.000 abstract 1
- 208000016604 Lyme disease Diseases 0.000 abstract 1
- 108700006640 OspA Proteins 0.000 abstract 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 abstract 1
- 241000125945 Protoparvovirus Species 0.000 abstract 1
- 206010037742 Rabies Diseases 0.000 abstract 1
- 208000014058 canine distemper Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 241000701161 unidentified adenovirus Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/828—Bacterial vaccine for canidae or mustelidae, e.g. dogs, foxes, minks
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/829—Bacterial vaccine for equine species, e.g. horses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/802—Virus-based particle
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/918—Immunological
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Dental Preparations (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/812,348 US6368603B1 (en) | 1997-03-05 | 1997-03-05 | Lyme combination compositions and uses |
| PCT/US1998/004135 WO1998039028A1 (en) | 1997-03-05 | 1998-03-04 | Lyme combination compositions and uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0988051T3 true DK0988051T3 (da) | 2008-10-13 |
Family
ID=25209312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK98908885T DK0988051T3 (da) | 1997-03-05 | 1998-03-04 | Lyme-kombinationspræparater og anvendelser |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6368603B1 (ja) |
| EP (1) | EP0988051B1 (ja) |
| JP (1) | JP4301415B2 (ja) |
| CN (1) | CN1252730A (ja) |
| AT (1) | ATE399021T1 (ja) |
| AU (1) | AU746185B2 (ja) |
| BR (1) | BR9808821A (ja) |
| CA (1) | CA2283420C (ja) |
| DE (1) | DE69839640D1 (ja) |
| DK (1) | DK0988051T3 (ja) |
| ES (1) | ES2310004T3 (ja) |
| HU (1) | HU228709B1 (ja) |
| IL (2) | IL131678A0 (ja) |
| PL (1) | PL190989B1 (ja) |
| PT (1) | PT988051E (ja) |
| WO (1) | WO1998039028A1 (ja) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA964896B (en) * | 1995-06-07 | 1997-01-08 | Connaught Lab | Expression of lipoproteins |
| CA2326408A1 (en) * | 1998-03-02 | 1999-09-10 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Epitope peptides immunogenic against streptococcus pneumoniae |
| WO2000078800A2 (en) * | 1999-06-18 | 2000-12-28 | Medimmune, Inc. | Combined decorin binding protein and outer surface protein compositions and methods of use |
| DE10162434A1 (de) * | 2001-12-18 | 2003-09-25 | November Ag Molekulare Medizin | Expressionsvektor und Verfahren zur Herstellung eines Expressionsvektors |
| US7906311B2 (en) | 2002-03-20 | 2011-03-15 | Merial Limited | Cotton rat lung cells for virus culture |
| US20040197339A1 (en) * | 2003-01-29 | 2004-10-07 | Brown Paul R. | Vaccine for Lyme disease |
| EP2390352A1 (en) | 2003-03-18 | 2011-11-30 | Quantum Genetics Ireland Limited | Systems and methods for improving protein and milk production of dairy herds |
| US7468273B2 (en) | 2003-05-01 | 2008-12-23 | Meial Limited | Canine GHRH gene, polypeptides and methods of use |
| ES2417019T3 (es) | 2003-11-13 | 2013-08-05 | University Of Georgia Research Foundation, Inc. | Procedimiento de caracterización del virus de la enfermedad de la bursitis infecciosa |
| MXPA06009452A (es) | 2004-02-19 | 2007-03-15 | Univ Alberta | Polimorfismos del promotor de leptin y sus usos. |
| EP2198881A1 (en) | 2005-04-25 | 2010-06-23 | Merial Limited | Nipah virus vaccines |
| US20080241184A1 (en) | 2005-08-25 | 2008-10-02 | Jules Maarten Minke | Canine influenza vaccines |
| US7771995B2 (en) | 2005-11-14 | 2010-08-10 | Merial Limited | Plasmid encoding human BMP-7 |
| EP2186823A1 (en) | 2005-11-14 | 2010-05-19 | Merial Limited | Gene therapy for renal failure |
| US7682619B2 (en) * | 2006-04-06 | 2010-03-23 | Cornell Research Foundation, Inc. | Canine influenza virus |
| US7862821B2 (en) | 2006-06-01 | 2011-01-04 | Merial Limited | Recombinant vaccine against bluetongue virus |
| EP2077856B1 (en) * | 2006-11-03 | 2015-08-12 | Intervet International BV | Canine lyme disease vaccine |
| SI2147105T1 (sl) | 2007-05-02 | 2013-08-30 | Merial Limited | DNA-plazmidi z izboljšano ekspresijo in stabilnostjo |
| DK2998315T4 (da) | 2009-04-03 | 2022-02-07 | Boehringer Ingelheim Animal Health Usa Inc | Newcastle sygdomsvirus-bårne fuglevacciner |
| EP3705133B1 (en) * | 2010-05-14 | 2024-06-26 | Baxalta Incorporated | Ospa chimeras and use thereof in vaccines |
| CN103269714B (zh) | 2010-08-31 | 2016-06-29 | 梅里亚有限公司 | 以新城疫病毒为载体的疱疹病毒疫苗 |
| WO2012090073A2 (en) | 2010-12-30 | 2012-07-05 | The Netherlands Cancer Institute | Methods and compositions for predicting chemotherapy sensitivity |
| US20140287931A1 (en) | 2011-04-04 | 2014-09-25 | Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis | Methods and compositions for predicting resistance to anticancer treatment |
| WO2012138783A2 (en) | 2011-04-04 | 2012-10-11 | Netherlands Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment |
| US9216213B2 (en) | 2011-04-20 | 2015-12-22 | Merial, Inc. | Adjuvanted rabies vaccine with improved viscosity profile |
| EP2701736A1 (en) | 2011-04-25 | 2014-03-05 | Advanced Bioscience Laboratories, Inc. | Truncated hiv envelope proteins (env), methods and compositions related thereto |
| EP2714077B1 (en) | 2011-06-01 | 2018-02-28 | Merial, Inc. | Needle-free administration of prrsv vaccines |
| ES2626297T3 (es) | 2011-08-12 | 2017-07-24 | Merial, Inc. | Preservación asistida por vacío de productos biológicos, en particular de vacunas |
| WO2013093629A2 (en) | 2011-12-20 | 2013-06-27 | Netherlands Cancer Institute | Modular vaccines, methods and compositions related thereto |
| WO2013138776A1 (en) | 2012-03-16 | 2013-09-19 | Merial Limited | Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g |
| EP2968514A1 (en) | 2013-03-12 | 2016-01-20 | Merial, Inc. | Reverse genetics schmallenberg virus vaccine compositions, and methods of use thereof |
| MX2017005687A (es) | 2014-11-03 | 2017-08-21 | Merial Inc | Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia. |
| PL3313864T3 (pl) | 2015-06-23 | 2022-01-03 | Boehringer Ingelheim Animal Health USA Inc. | Rekombinowane wektory wirusowe zawierające drugorzędne białko prrsv oraz sposoby ich wytwarzania i zastosowania |
| CN109310776B (zh) | 2016-04-14 | 2022-02-11 | 勃林格殷格翰动物保健美国公司 | 含有抗微生物的聚酰胺或奥替尼啶防腐剂的多次剂量组合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK590288D0 (da) * | 1988-10-24 | 1988-10-24 | Symbicom Ab | Kemiske forbindelser |
| US5266313A (en) | 1987-02-03 | 1993-11-30 | The United States Of America As Represented By The Department Of Health And Human Services | Raccoon poxvirus as a gene expression and vaccine vector for genes of rabies virus and other organisms |
| DK0465204T3 (da) * | 1990-07-06 | 2000-10-09 | American Home Prod | Vaccine mod Lyme sygdom |
| US5843456A (en) * | 1991-03-07 | 1998-12-01 | Virogenetics Corporation | Alvac poxvirus-rabies compositions and combination compositions and uses |
| CA2123121A1 (en) | 1991-11-12 | 1993-05-27 | Anthony C. Caputa | Recombinant vaccine against lyme disease |
| US5656451A (en) * | 1993-07-30 | 1997-08-12 | Yale University | OspE, OspF, and S1 polypeptides in borrelia burgdorferi |
| US5728385A (en) * | 1993-08-12 | 1998-03-17 | Classen Immunotherapies, Inc. | Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae |
| FR2751227B1 (fr) * | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives |
-
1997
- 1997-03-05 US US08/812,348 patent/US6368603B1/en not_active Expired - Lifetime
-
1998
- 1998-03-04 AU AU66807/98A patent/AU746185B2/en not_active Expired
- 1998-03-04 CN CN98804390A patent/CN1252730A/zh active Pending
- 1998-03-04 DE DE69839640T patent/DE69839640D1/de not_active Expired - Lifetime
- 1998-03-04 DK DK98908885T patent/DK0988051T3/da active
- 1998-03-04 AT AT98908885T patent/ATE399021T1/de active
- 1998-03-04 ES ES98908885T patent/ES2310004T3/es not_active Expired - Lifetime
- 1998-03-04 HU HU0001401A patent/HU228709B1/hu unknown
- 1998-03-04 WO PCT/US1998/004135 patent/WO1998039028A1/en active IP Right Grant
- 1998-03-04 IL IL13167898A patent/IL131678A0/xx active IP Right Grant
- 1998-03-04 EP EP98908885A patent/EP0988051B1/en not_active Expired - Lifetime
- 1998-03-04 CA CA002283420A patent/CA2283420C/en not_active Expired - Lifetime
- 1998-03-04 BR BR9808821-1A patent/BR9808821A/pt not_active Application Discontinuation
- 1998-03-04 JP JP53869998A patent/JP4301415B2/ja not_active Expired - Lifetime
- 1998-03-04 PL PL335731A patent/PL190989B1/pl unknown
- 1998-03-04 PT PT98908885T patent/PT988051E/pt unknown
-
1999
- 1999-09-01 IL IL131678A patent/IL131678A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2310004T3 (es) | 2008-12-16 |
| DE69839640D1 (de) | 2008-08-07 |
| EP0988051A4 (en) | 2004-11-17 |
| JP2001513112A (ja) | 2001-08-28 |
| IL131678A (en) | 2006-12-31 |
| JP4301415B2 (ja) | 2009-07-22 |
| PT988051E (pt) | 2008-08-13 |
| CA2283420A1 (en) | 1998-09-11 |
| AU6680798A (en) | 1998-09-22 |
| WO1998039028A1 (en) | 1998-09-11 |
| EP0988051A1 (en) | 2000-03-29 |
| EP0988051B1 (en) | 2008-06-25 |
| CA2283420C (en) | 2008-07-22 |
| IL131678A0 (en) | 2001-03-19 |
| BR9808821A (pt) | 2000-10-24 |
| AU746185B2 (en) | 2002-04-18 |
| US6368603B1 (en) | 2002-04-09 |
| HUP0001401A3 (en) | 2005-10-28 |
| ATE399021T1 (de) | 2008-07-15 |
| PL190989B1 (pl) | 2006-02-28 |
| PL335731A1 (en) | 2000-05-08 |
| CN1252730A (zh) | 2000-05-10 |
| HUP0001401A2 (en) | 2000-07-28 |
| HU228709B1 (en) | 2013-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0988051T3 (da) | Lyme-kombinationspræparater og anvendelser | |
| CY1121353T1 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις | |
| EA200300137A1 (ru) | Анти-il-12-антитела, композиции, способы и применения | |
| NO20014605D0 (no) | Humane antistoff som binder human IL-12 samt fremgangsmåter ved fremstilling derav | |
| BRPI0417547A (pt) | sistema e método de transferência segura de informações | |
| PT2105449T (pt) | Agentes antagonísticos de ligação selectiva da proteína de ligação da osteoprotegerina | |
| ATE297980T1 (de) | Verfahren zur klonierung von schweinen | |
| NO20030621L (no) | Anti-dual integrinantistoffer, sammensetninger, fremgangsmater og anvendelser | |
| DK1301539T3 (da) | Antigenbindende fragmenter, der er specifikke for dendristiske celler, sammensætninger og fremgangsmåder til anvendelse deraf, antigener, der genkendes deraf, og celler opnået derved | |
| ATE258598T1 (de) | Verfahren zur proteinrückfaltung durch verwendung zwitterionischer wirkstoffe von niedrigem molekulargewicht | |
| ATE162550T1 (de) | Ospc-antigen-impfstoffe immunogene zusammensetzung zur vorbeugung und behandlung von lyme-krankheit und rekombinante verfahren zur herstellung von derartige antigene | |
| RU2009120894A (ru) | Вакцина против лаймской болезни собак | |
| DE69737323D1 (de) | Adhesin aus heliobacter pylori, welches an blutgruppenantigene bindet | |
| WO2001057219A3 (en) | Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods | |
| ES2093286T3 (es) | Bencimidazoles, medicamentos que contienen estos compuestos y procedimiento para su preparacion. | |
| WO2003102017A3 (en) | Anti-relp fusion antibodies, compositions, methods and uses | |
| ATE205822T1 (de) | Substituierte 4-arylbutyrsäurederivate als matrix metalloprotease inhibitoren | |
| BR0017102A (pt) | Agente de liberação, e, método para formar materiais lignocelulósicos ligados com aglutinante de poliisocianato orgânico | |
| DE59809344D1 (de) | Disubstituierte biphenyloxazoline | |
| DE602004023311D1 (de) | Antigen-zufuhrsystem | |
| AR030133A1 (es) | Anticuerpos anti-tnf, composiciones, metodos y usos | |
| IT238252Y1 (it) | Attrezzo per allenare giocatori di squadre di calcio | |
| CO5160334A1 (es) | Derivados de 1,4-benzotiazepina-1,1-dioxido sustituidos con aldosas y cetosas, procedimiento para su preparacion y medicamentos que los contienen | |
| BR1100559B1 (pt) | mÉtodo de sondagem para identificar anticorpos especÍficos para antÍgenos selecionados. |